Future research is needed to find out whether PI3K/mTOR inhibition combined with an MEK inhibitor has potential for KRAS A146–mutated tumor and if the poor long-term tolerability found in other advanced solid tumors48 is also pertinent in patients with KRAS A146 mutant tumors. The gene discussed is KRAS; the disease is neoplasm.